Scarica l'app Stockscreener
2.00
2.04%
0.04
Dopo l'orario di chiusura:
1.99
-0.01
-0.50%
Precedente Chiudi:
$1.96
Aprire:
$1.96
Volume 24 ore:
4.10M
Relative Volume:
0.44
Capitalizzazione di mercato:
$690.31M
Reddito:
$22,000
Utile/perdita netta:
$-190.89M
Rapporto P/E:
-2.3036
EPS:
-0.8682
Flusso di cassa netto:
$-149.63M
1 W Prestazione:
+0.00%
1M Prestazione:
-16.32%
6M Prestazione:
+62.60%
1 anno Prestazione:
+83.49%
Intervallo 1D:
$1.955
$2.05
Intervallo di 1 settimana:
$1.84
$2.06
Portata 52W:
$0.9842
$4.46
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Nome
Allogene Therapeutics Inc
Settore
Industria
Telefono
(650) 457-2700
Indirizzo
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALLO
Allogene Therapeutics Inc
|
2.00 | 676.50M | 22,000 | -190.89M | -149.63M | -0.8682 |
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.03B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
638.88 | 67.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.46 | 50.76B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
297.45 | 40.12B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
151.56 | 32.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-16 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2026-04-10 | Ripresa | Jefferies | Buy |
| 2026-01-09 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2025-10-10 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-05-14 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2025-03-14 | Aggiornamento | Citizens JMP | Mkt Perform → Mkt Outperform |
| 2024-08-08 | Ripresa | Oppenheimer | Outperform |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-01-05 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-05 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-08 | Iniziato | Citigroup | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-01-24 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-06 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-12-12 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-08-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-07-15 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-06-03 | Iniziato | Robert W. Baird | Neutral |
| 2022-02-28 | Reiterato | B. Riley Securities | Buy |
| 2021-10-20 | Iniziato | Cowen | Outperform |
| 2021-10-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-10-08 | Downgrade | Stifel | Buy → Hold |
| 2021-09-23 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-06-21 | Ripresa | Jefferies | Buy |
| 2021-05-20 | Aggiornamento | Truist | Hold → Buy |
| 2021-05-14 | Iniziato | B. Riley Securities | Buy |
| 2021-01-26 | Aggiornamento | Stifel | Hold → Buy |
| 2020-12-10 | Ripresa | H.C. Wainwright | Buy |
| 2020-11-24 | Iniziato | BofA Securities | Buy |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-06-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-29 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-19 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2020-05-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-05-14 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-14 | Downgrade | SunTrust | Buy → Hold |
| 2020-04-13 | Iniziato | SunTrust | Buy |
| 2020-03-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-24 | Iniziato | Berenberg | Hold |
| 2019-12-18 | Iniziato | JMP Securities | Mkt Outperform |
| 2019-11-04 | Iniziato | Canaccord Genuity | Buy |
| 2019-08-09 | Iniziato | BTIG Research | Buy |
| 2019-06-05 | Iniziato | ROTH Capital | Neutral |
| 2019-05-31 | Iniziato | Guggenheim | Neutral |
| 2019-05-23 | Iniziato | Stifel | Hold |
| 2019-03-29 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Allogene Therapeutics Inc Borsa (ALLO) Ultime notizie
Allogene Therapeutics posts narrower-than-expected loss in Q1 - MSN
Allogene Therapeutics explores ALPHA3 trial potential for allogeneic CAR T in LBCL treatment - Traders Union
JPMorgan, Allogene Therapeutics and other big stocks moving lower in Tuesday's pre-market session - MSN
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss By Investing.com - Investing.com South Africa
Earnings call transcript: Allogene Therapeutics Q1 2026 sees mixed results with revenue miss - Investing.com UK
ALLO Technical Analysis | Trend, Signals & Chart Patterns | ALLOGENE THERAPEUTICS INC (NASDAQ:ALLO) - ChartMill
Number of shareholders of Allogene Therapeutics, Inc. – BOATS:ALLO - TradingView
Allogene outlines cash runway into Q1 2029 while raising 2026 operating cash expense guidance to ~$165M - MSN
Allogene Therapeutics unveils ALLO-329 with Dagger technology for next generation cell therapy - Traders Union
Citadel affiliates, Kenneth Griffin report stakes in Allogene (ALLO) - Stock Titan
Lynx1 amends 13G for Allogene Therapeutics (NASDAQ: ALLO) showing 0% stake - Stock Titan
Allogene Therapeutics | SCHEDULE 13G/A: Others - Moomoo
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $7 to $14 - Moomoo
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q1 2026 Earnings Call Transcript - Insider Monkey
Piper Sandler Sticks to Their Buy Rating for Allogene Therapeutics (ALLO) - The Globe and Mail
Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO) - The Globe and Mail
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN) - The Globe and Mail
A Quick Look at Today's Ratings for Allogene Therapeutics(ALLO.US), With a Forecast Between $9 to $14 - Moomoo
Allogene Therapeutics (NASDAQ:ALLO) Shares Down 7.7%Here's What Happened - MarketBeat
Allogene Therapeutics Posts Narrower-Than-Expected Loss in Q1 - The Globe and Mail
Oppenheimer Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $7 - Moomoo
RBC Capital Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Piper Sandler Maintains Allogene Therapeutics(ALLO.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Transcript : Allogene Therapeutics, Inc., Q1 2026 Earnings Call, May 13, 2026 - marketscreener.com
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and Financial Strength - GuruFocus
TD Cowen Maintains Allogene Therapeutics(ALLO.US) With Buy Rating - Moomoo
ALLO Adjusts 2026 Operating Expense Guidance - GuruFocus
Allogene Therapeutics Q1 Earnings Call Highlights - MarketBeat
Allogene Therapeutics ends China cell therapy deal with Overland - 1470 & 100.3 WMBD
Allogene Therapeutics (NASDAQ: ALLO) Belldegrun reports 13.47M-share stake - Stock Titan
ALLO Secures Funding, Extends Cash Runway to 2029 - GuruFocus
Allogene (ALLO) Q1 2026 Earnings Transcript - The Globe and Mail
ALLO: Interim data show robust efficacy and safety for cema-cel and early promise for ALLO-329, with solid financials - TradingView
Allogene Therapeutics Q1 Net Loss Narrows - Moomoo
Allogene Therapeutics Q1 2026 Earnings Call Transcript - Benzinga
Earnings call transcript: Allogene Therapeutics beats EPS expectations in Q1 2026 - Investing.com
Allogene Therapeutics releases Q1 corporate update with focus on allogeneic cell therapy progress - Traders Union
Allogene Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Allogene Highlights ALPHA3 Data and Extended Cash Runway - TipRanks
Is Allogene Therapeutics (ALLO) Undervalued After Q1 2026? EPS - GuruFocus
Allogene Therapeutics (ALLO) insider holdings: Dr. Chang 4.9% ownership disclosed - Stock Titan
Allogene TherapeuticsEnters Termination Agreement With Overland Therapeutics On May 12, 2026SEC Filing - TradingView
Earnings Flash (ALLO) Allogene Therapeutics Posts Q1 Loss $0.18, vs. FactSet Est of $0.19 Loss - marketscreener.com
Allogene Therapeutics: Q1 Earnings Snapshot - 10TV
Allogene (NASDAQ: ALLO) extends cash runway to 2029 as CAR T trials advance - Stock Titan
Allogene Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Allogene (NASDAQ: ALLO) posts Q1 2026 loss, updates ALPHA3 data and cash runway - Stock Titan
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update - GlobeNewswire
More on Allogene Therapeutics - MSN
Allogene Therapeutics Q1 2026 earnings preview - MSN
Allogene Therapeutics Inc (ALLO) Q1 2026 Earnings Call Highlights: Promising Trial Results and ... By GuruFocus - Investing.com Canada
Allogene Therapeutics Inc Azioni (ALLO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.98%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):